A reflection paper is a document that outlines the view of the European Medicines Agency (EMA) or one of its committees, working parties, or other groups on a specific issue related to medicines or healthcare. It serves as a means of providing guidance, initiating discussions, and seeking input from stakeholders on important topics relevant to the regulation and use of medicines.
Reflection papers are typically published by the EMA or its committees to address emerging scientific, regulatory, or public health issues that require further exploration or clarification. They aim to provide a comprehensive and balanced overview of the agency’s current thinking, scientific expertise, and regulatory considerations on the particular subject matter.
These papers may cover a wide range of topics, including specific therapeutic areas, regulatory requirements, scientific methodologies, safety concerns, or emerging trends in healthcare. They are based on scientific evidence, expert opinions, and an analysis of available data.
The purpose of a reflection paper is to stimulate discussion and gather input from stakeholders, including healthcare professionals, industry representatives, patient organizations, and regulatory authorities. The EMA or its committees often invite public consultation and feedback on the content of the reflection paper, allowing for a broader perspective and consideration of different viewpoints.
Confounding by Indication
Contact our experts today
Composed of proven experts from the pharmaceutical industry, our team is ready to answer to your needs in any
area of product development, commercialisation and early access programs, and life cycle management